Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | AADAC | P22760 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10437873 | 0.87 | AR (0.56) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11929282 | 0.82 | AR (0.51) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL8407379 | 0.82 | AR (0.50) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL15969823 | 0.82 | AR (0.47) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL8407240 | 0.82 | AR (0.56) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL5452124 | 0.80 | MAPT (0.60) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL8410213 | 0.79 | AR (0.47) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11873015 | 0.78 | ALDH1A1 (0.46) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11514591 | 0.78 | MLYCD (0.51) | ARPGRMLYCD | |
| SCHEMBL11877918 | 0.76 | KMT2A (0.48) | ARCYP3A4CES2ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4144270-A | NITRO OR HALOGEN SUBSTITUTED CARBOCYCLIC AMIDES | SCHERING CORPORATION (US) | 1979-03-13 | — | — | US | claimed |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
| US-4161540-A | SUBSTITUTED ANILIDE | SCHERING CORPORATION (US) | 1979-07-17 | — | — | US | disclosed |
| US-4144270-A | NITRO OR HALOGEN SUBSTITUTED CARBOCYCLIC AMIDES | SCHERING CORPORATION (US) | 1979-03-13 | — | — | US | disclosed |
| US-4139638-A | NITRO OR HALOGEN SUBSTITUTED ANILIDES, ANTIANDROGENS, ACNE, CANCER | SCHERING CORPORATION (US) | 1979-02-13 | — | — | US | disclosed |
| US-3995060-A | SUBSTITUTED ANILIDES | SCHERING CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | AR 2079/4885CYP3A4 69/4885CES2 85/4885 |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | AADAC, PAICS, ABCG2 | AR 2079/4885CYP3A4 69/4885CES2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.